FDA qui­et­ly turns Keytru­da ac­cel­er­at­ed ap­proval for less-fre­quent dos­ing in­to full ap­proval

Mer­ck’s an­ti-PD-1 an­ti­body block­buster Keytru­da had a less-fre­quent dos­ing reg­i­men pre­vi­ous­ly cleared un­der an ac­cel­er­at­ed ap­proval con­vert­ed in­to full ap­provals on Dec. 16.

The ac­cel­er­at­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER